GlassScriptPhysician profile
Danielle Beken
NPI 1538835608
$722.16
in general payments reported to CMS, 2019-2025
12 companies · $370 in 2025
The $370 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $89.01 · 2024: $263 · 2025: $370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $722.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $722.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $170.07 | 2024-2025 | Repatha, Repatha |
| Medtronic, INC. | $119.11 | 2025 | Ffrangio, Venaseal |
| Pfizer INC. | $98.12 | 2023-2024 | |
| Inari Medical, INC. | $73.75 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Abiomed | $66.31 | 2024 | Impella |
| Astrazeneca Pharmaceuticals LP | $41.41 | 2025 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $35.98 | 2024 | Eliquis |
| Boston Scientific Corporation | $27.79 | 2025 | Accolade Sr |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $26.81 | 2024-2025 | Lifevest |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.85 | 2023 | Xifaxan |
| Janssen Pharmaceuticals, INC | $22.50 | 2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $17.46 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Beken listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.